Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tipranavir
Drug ID BADD_D02226
Description Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.
Indications and Usage For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
Marketing Status Prescription
ATC Code J05AE09
DrugBank ID DB00932
KEGG ID D08605
MeSH ID C107201
PubChem ID 54682461
TTD Drug ID D0EV6T
NDC Product Code 11014-0046; 12714-901; 0597-0003; 0597-0002
Synonyms tipranavir | tipranavir, (R-(R*,R*))-isomer | 3'-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2h-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide | Aptivus | tipranavir, (S-(R*,R*))-isomer | tipranavir, (S-(R*,S*))-isomer | tipranavir glucuronide | (2R)-3,6-Dihydro-6-oxo-2-(2-phenylethyl)-2-propyl-5-((1R)-1-(3-(((5-(trifluoromethyl)-2-pyridinyl)sulfonyl)amino)phenyl)propyl)-2H-pyran-4-yl beta-D-glucopyranosiduronic acid | tipranavir, (R-(R*,S*))-isomer | tipranavir C-14 | C14-tipranavir | 14C-tipranavir | tipranavir disodium | PNU-140690E | tipranavir sodium | PNU 140690 | PNU-140690
Chemical Information
Molecular Formula C31H33F3N2O5S
CAS Registry Number 174484-41-4
SMILES CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC= CC=C4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersensitivity10.01.03.003--
Hypertriglyceridaemia14.08.02.001--
Influenza like illness08.01.03.010--
Insomnia19.02.01.002; 17.15.03.002--
Lipase increased13.05.01.003--
Liver function test abnormal13.03.01.013--Not Available
Malaise08.01.01.003--
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.004--Not Available
Pancreatitis07.18.01.001--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Thrombocytopenia01.08.01.002--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
White blood cell count decreased13.01.06.012--
Lipodystrophy acquired23.07.01.003; 14.08.04.008--Not Available
Mitochondrial toxicity14.11.02.001; 12.03.01.009--Not Available
Haemorrhage24.07.01.002--Not Available
Facial wasting23.07.01.004; 14.08.04.004--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Hyperlipidaemia14.08.03.001--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages